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Abstract
Background: For patients with metastatic renal cell carcinoma (mRCC), targeted therapies have entered the market
since 2006. The aims of this study were to evaluate the uptake and use of targeted therapies for mRCC in The
Netherlands, examine factors associated with the prescription of targeted therapies in daily clinical practice and
study their effectiveness in terms of overall survival (OS).
Methods: Two cohorts from PERCEPTION, a population-based registry of mRCC patients, were used: a 2008–2010
Cohort (n = 645) and a 2011–2013 Cohort (n = 233). Chi-squared tests for trend were used to study time trends in
the use of targeted therapy. Patients were grouped based on the eligibility criteria of the SUTENT trial, the trial that
led to sunitinib becoming standard of care, to investigate the use of targeted therapies amongst patients fulfilling
those criteria. Multi-level logistic regression was used to identify patient subgroups that are less likely to receive
targeted therapies.
Results: Approximately one-third of patients fulfilling SUTENT trial eligibility criteria did not receive any targeted
therapy (29 % in the 2008–2010 Cohort; 35 % in the 2011–2013 Cohort). Patients aged 65+ years were less likely
to receive targeted therapy in both cohorts and different risk groups (odds ratios range between 0.84–0.92); other
factors like number of metastatic sites were of influence in some subgroups. Amongst treated patients, there was
a decreasing trend in sunitinib use over time (p = 0.0061), and an increasing trend in pazopanib use (p = 0.0005).
Conclusions: Targeted therapies have largely replaced interferon-alfa as first-line standard of care. Nevertheless,
many eligible patients in Dutch daily practice did not receive targeted therapies despite their ability to improve
survival. Reasons for their apparent underutilisation should be examined more carefully.
Keywords: Metastatic renal cell carcinoma, Targeted therapy, Uptake and use, Overall survival, Population-based
registry
Background
Kidney cancer accounts for about 3 % of all cancers with
an estimated incidence of 115,200 in Europe in 2012 [1].
Renal cell carcinoma (RCC) represents 90 % of all kidney
cancers [2]. The prognosis is relatively good for patients
with localised disease, which can be treated with surgery,
but the prognosis of patients with advanced or meta-
static disease (mRCC) is poor [3].
Targeted therapies for mRCC have entered the market
since 2006, sunitinib being the first. Sunitinib increased
median progression-free survival (PFS) from five to
11 months [4], and overall survival (OS) from 22 to
26 months compared to interferon-alfa (IFN-a) in mRCC
patients with a clear-cell histology [5]. Subsequently, it
became standard of care for patients with a good or
intermediate prognosis according to the Memorial Sloan
Kettering Cancer Center (MSKCC) risk score [6]. Re-
cently, the effectiveness of sunitinib was demonstrated
in a broader ‘real-world’ population [7]. Bevacizumab (in
combination with IFN-a) and pazopanib were added to
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guidelines as first-line therapies for patients with a good
or intermediate prognosis in 2009 and 2010, respectively
[6, 8]. For patients with a poor prognosis, temsirolimus
was recommended [6] following the results of a multi-
centre, phase III trial in mRCC patients without any re-
strictions in histologic type, showing an increase in OS
from seven to 11 months compared to IFN-a [9]. Fur-
thermore, a number of second-line therapies have been
added to guidelines, such as sorafenib, everolimus and
axitinib [6, 10].
Obviously, full and swift implementation of guidelines
into clinical practice is essential to maximise the benefits
of new therapies. However, the adoption of innovations
in cancer care is generally quite heterogeneous, and dif-
fers between countries, and regions within countries
[11]. A study by Jonsson et al. showed widespread use of
sunitinib in the eight of the countries they studied, des-
pite small differences between countries [12]. Sorafenib
was widely prescribed in France, while a very low uptake
and use in the United Kingdom and the United States
were found. Besides between-country variation, Jonsson
et al. found within-country variation in Sweden and sug-
gested that more detailed information is needed on the
use of first- and second-line therapies, to determine the
extent of potential under- and overconsumption in dif-
ferent regions and different patient populations [12].
The aims of this study were to evaluate the uptake and
use of targeted therapies for mRCC in The Netherlands,
examine factors associated with the prescription of tar-
geted therapies in daily clinical practice and study their
effectiveness in terms of OS.
Methods
Study population
A population-based registry (entitled PERCEPTION)
was created to include patients with mRCC. The PER-
CEPTION registry consisted of two parts; a retrospective
study and a prospective study. In the retrospective study,
eligible patients were selected from the Netherlands
Cancer Registry (NCR), which maintains a cancer regis-
tration database of all cancer patients in The
Netherlands. Inclusion criteria for the retrospective
study comprised a diagnosis of mRCC (i.e. metastases at
initial presentation) of any histological subtype. Patients
diagnosed from January 2008 until December 2010 in 42
of 51 hospitals (both general and academic) in four re-
gions, covering approximately half of the country, were
included. All patients were followed for a minimum of
three years or until death (2008–2010 Cohort).
The prospective study was designed differently in
order to measure additional aspects of the disease, such
as health-related quality of life (not reported in this
study). In the prospective study, patients with RCC (all
stages) of any histological subtype diagnosed from 2011
until June 30th 2013 in 25 of 32 hospitals (both general
and academic) in three regions were included. In con-
trast to the 2008–2010 Cohort, this cohort also com-
prised patients with mRCC who were initially diagnosed
with localised disease. Besides the NCR, the hospitals’ fi-
nancing systems were used to select eligible patients at
an early phase (for quality of life measurements). All pa-
tients were followed until the end of 2013 or until death
(2011–2013 Cohort).
Data collection
Data on baseline demographics, clinical and laboratory
factors were retrospectively collected from individual pa-
tient records by using uniform case report forms to en-
sure consistent data collection. Furthermore, data on
treatment schemes and treatment endpoints (e.g. sur-
vival) were collected. Laboratory factors, such as haemo-
globin and corrected calcium levels, were standardised
according to routinely used reference values. Data were
collected by personnel of the NCR and data collection
stopped at the end of 2013.
Statistical analyses
To study differences in the proportion of patients receiv-
ing targeted therapy per half a year chi-squared tests
were used. Exact tests were used to study possible time
trends in the use of different therapies amongst treated
patients. Additionally, chi-squared tests for trend were
conducted.
Then, the use of targeted therapies within risk groups
was studied. Risk groups were created using a slightly
modified version of the MSKCC risk score [3]; a time
from initial diagnosis to metastatic diagnosis of less than
one year was used as a risk factor instead of a time from
initial diagnosis to initiation of treatment of less than
one year, since many patients in the study population
did not receive any targeted therapy, thereby making it
impossible to calculate the time to treatment. Addition-
ally, the WHO performance status was used instead of
Karnofsky performance status.
Furthermore, patients were grouped based on the eli-
gibility criteria of the SUTENT trial [4], the trial that led
to sunitinib becoming standard of care, to investigate
the use of targeted therapies amongst patients fulfilling
those criteria. Patients who had a clear-cell subtype, a
WHO performance status of 0 or 1 and no brain metas-
tases were classified as fulfilling the SUTENT trial eligi-
bility criteria.
To identify patient subgroups that are less likely to re-
ceive targeted therapies in daily clinical practice among
patients fulfilling SUTENT trial eligibility criteria, multi-
level mixed-effects logistic regression was used to ac-
count for between-hospital variance. At the patient-level,
patient and disease characteristics were taken into
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account including baseline demographics, clinical and la-
boratory factors [13, 14]. Backward selection was used to
select the covariates for the models; any non-significant
covariates were excluded from the models one at a time.
OS was calculated from the start of therapy until death
from any cause or the date of last follow-up, whichever
came first, using the Kaplan-Meier method. For patients
not receiving any targeted therapy, OS was calculated
from the date of diagnosis.
Missing data regarding baseline characteristics were
handled using multiple imputations by chained equa-
tions. This method generated imputations based on a set
of imputation models, one for each variable with missing
values [15].
All analyses were performed separately for the 2008–
2010 Cohort and the 2011–2013 Cohort, because of dif-
ferences in inclusion criteria, patient selection and dur-
ation of follow-up. The significance level was set at α =
0.10. Data analyses were conducted using STATA statis-
tical analysis software (StataCorp. 2013. Stata Statistical
Software: Release 13. College Station, TX: StataCorp LP).
Results
Patient and disease characteristics of the 2008–2010
Cohort
714 patients newly diagnosed with mRCC between 2008
and 2010 were identified. Of these patients 69 were ex-
cluded (Additional file 1: Figure S1), leaving 645 patients
for data analysis. These patients were uniformly distrib-
uted across the three-year period since 213 patients were
diagnosed in 2008, 216 in 2009 and 216 in 2010. Median
follow-up was 3.3 years (95 % C.I.: 3.2–3.6).
Table 1 shows the patient and disease characteristics
for this cohort. Median age was 66 years (range 23–93)
and the majority of patients was male (66 %). The distri-
bution of patients according to the MSKCC risk score
showed a high proportion of patients (58 %) with a poor
prognosis (versus 42 % with an intermediate prognosis).
Since all patients in the 2008–2010 Cohort presented
with metastatic disease, none of them had a favourable
prognosis (i.e. time from initial diagnosis was less than
one year). Additional file 1: Table S1 provides the ob-
served patient and disease characteristics (without
imputations).
Uptake of targeted therapies and their use in daily
clinical practice (2008–2010 Cohort)
Table 2 shows the first-line therapies used in the 2008–
2010 Cohort. 336/645 patients (52 %) received a first-
line therapy with the majority (282, 84 %) treated with
sunitinib. The distribution of patients across first-line
therapies (per half-year period) is presented in Fig. 1.
There is evidence of a difference between the half-year
periods in the proportion of patients receiving targeted
therapy (p = 0.041), but the chi-squared test for trend
did not yield a significant result. Furthermore, no shift
was found in the use of first-line therapies amongst
treated patients.
Of the 336 patients receiving first-line therapy, 101 pa-
tients (30 %) also received a second-line therapy, with
everolimus being the most common (40 %), followed by
sorafenib (28 %). There was an increasing trend in
everolimus use over time (p < 0.0001) and a decreasing
trend in sorafenib use (p < 0.0001); from 2010 onwards,
everolimus largely replaced sorafenib.
Use of targeted therapies amongst patients with an
intermediate prognosis (2008–2010 Cohort)
Forty-two percent (269/645) of the patients in the 2008–
2010 Cohort had an intermediate prognosis.
105/269 patients (39 %) received no targeted therapy.
Some (n = 15) of these patients received a metastasect-
omy (combined with a nephrectomy) with a possible
curative intention, making systemic therapy redundant.
40 of the remaining 90 patients (44 %) who were given
neither targeted therapy nor a metastasectomy (com-
bined with a nephrectomy) fulfilled the SUTENT trial
eligibility criteria, indicating that they might have been
eligible for treatment with sunitinib or another targeted
therapy. 164/269 patients (61 %) received a first-line
treatment; the majority was treated with sunitinib (145/
164; 88 %). Of the 145 patients treated with sunitinib,
102 fulfilled the SUTENT trial eligibility criteria.
In patients fulfilling SUTENT trial eligibility criteria
(including patients not receiving any targeted therapy
and patients treated with sunitinib), patients with an ab-
normal neutrophil count (OR, 0.28; p = 0.045) were less
likely to receive sunitinib, whereas patients with more
than one metastatic site (OR, 3.35; p = 0.010) were more
likely to receive sunitinib after adjustment for additional
patient and disease characteristics (see frequencies in
Table 3).
The median OS of eligible patients not receiving any
targeted therapy was 18.6 months (95 % C.I. 8.4–33.7).
Table 4 presents the median OS in subgroups of patients
with an intermediate prognosis treated with first-line su-
nitinib. Median OS of eligible patients treated with suni-
tinib was 14.8 months (95 % C.I. 10.8–16.1). Note that a
different starting point was used for the survival analysis
(compared to the survival analysis in patients not receiv-
ing any targeted therapy). The mean time from diagnosis
to start of first-line sunitinib was 4.3 months (standard
deviation [SD] 6.0).
Median OS was 11.9 months (95 % C.I. 6.5–18.3) for
ineligible patients treated with sunitinib, which was not
significantly shorter than the OS of eligible patients
treated with sunitinib. No significant differences were
observed within the other subgroups.
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Table 1 Patient and disease characteristics 2008–2010 Cohort and 2011–2013 Cohort
2008–2010 Cohort: mRCC at the initial diagnosis (n = 621) 2011–2013 Cohort: mRCC (n = 221)
Sex - n (%)
Female 213 34 % 60 27 %
Male 408 66 % 161 73 %
Median age - yr (range) 66 23–93 66 27–93
Histology - n (%)
Clear cell 354 57 % 152 69 %
Othera 267 43 % 69 31 %
WHO performance status - n (%)
0–1 430 69 % 178 81 %
2–4 191 31 % 42 19 %
Site of metastasis - n (%)
One 206 33 % 87 39 %
more than one 415 67 % 134 61 %
Liver metastasis - n (%)
No 509 82 % 175 79 %
Yes 112 18 % 46 21 %
Lung metastasis - n (%)
No 173 28 % 74 33 %
Yes 448 72 % 147 67 %
Bone metastasis - n (%)
No 393 63 % 158 71 %
Yes 228 37 % 63 29 %
Brain metastasis - n (%)
No 571 92 % 200 90 %
Yes 50 8 % 16 7 %
Haemoglobin - n (%)
Normal 205 33 % 85 38 %
< LLN 416 67 % 136 62 %
Neutrophil count - n (%)
Normal 383 62 % 152 69 %
> ULN 238 38 % 69 31 %
Platelet count - n (%)
Normal 452 73 % 159 72 %
> ULN 169 27 % 62 28 %
Albumin - n (%)
Normal 391 63 % 130 59 %
< LLN 230 37 % 91 41 %
Corrected serum calcium - n (%)
Normal 421 68 % 140 63 %
> ULN 200 32 % 81 37 %
Alkaline phosphatase - n (%)
Normal 432 70 % 152 69 %
> ULN 189 30 % 69 31 %
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Table 1 Patient and disease characteristics 2008–2010 Cohort and 2011–2013 Cohort (Continued)
Lactate dehydrogenase - n (%)
Normal 372 60 % 179 81 %
>1.5 times ULN 249 40 % 42 19 %
Comorbidities - n (%)
0–1 356 57 % 151 68 %
>1 265 43 % 67 30 %
Time since RCC diagnosis
> one year NA NA 16 7 %
< one year NA NA 204 92 %
NOTE: 24 patients in the 2008–2010 Cohort and 12 patients in the 2010–2013 Cohort were excluded from this table, since these patients received a
metastasectomy (combined with a nephrectomy) with a possible curative intention, making systemic treatment redundant
Abbreviations: LLN lower limit of normal, ULN upper limit of normal, NA not applicable
amRCC was clinically established without histopathological confirmation in 17 % of patients and mRCC was classified as not otherwise specified without further
subtyping in 13 % of patients (Cohort 2008–2010). It is likely that a substantial proportion of these patients had a clear cell subtype
Table 2 Treatment patterns 2008–2010 Cohort and 2011–2013 Cohort
2008–2010 Cohort: mRCC at the initial diagnosis 2011–2013 Cohort: mRCC
All patients
(n = 645)
Intermediate
prognosis
(n = 269)
Poor prognosis
(n = 376)
All patients
(n = 233)
Favourable/
intermediate
prognosis (n = 136)
Poor prognosis
(n = 97)
No systemic
therapy
309
(48 %)
105
(39 %)
204
(54 %)
94
(40 %)
52
(38 %)
42
(43 %)
First-line therapy 336
(52 %)
336
(100 %)
164
(61 %)
164
(100 %)
172
(46 %)
172
(100 %)
139
(60 %)
139
(100 %)
84
(62 %)
84
(100 %)
55
(57 %)
55
(100 %)
Sunitinib 282 (84 %) 145 (88 %) 137 (80 %) 110 (79 %) 66 (79 %) 44 (80 %)
Temsirolimus 24 (7 %) 5 (3 %) 19 (11 %) 3 (2 %) 1 (1 %) 2 (4 %)
Sorafenib 11 (3 %) 7 (4 %) 4 (2 %) 4 (3 %) 3 (4 %) 1 (2 %)
Bevacizumab +
IFN-a
6 (2 %) 2 (1 %) 4 (2 %) 2 (1 %) 1 (1 %) 1 (2 %)
Pazopanib 4 (2 %) 4 (2 %) 0 (0 %) 11 (8 %) 7 (8 %) 4 (7 %)
IFN-a 3 (1 %) 0 (0 %) 3 (2 %) 1 (1 %) 0 (0 %) 1 (2 %)
Everolimus 3 (1 %) 1 (1 %) 2 (1 %) 2 (1 %) 1 (1 %) 1 (2 %)
Pazopanib-
everolimus
0 (0 %) 0 (0 %) 0 (0 %) 3 (2 %) 3 (4 %) 0 (0 %)
Other 3 (1 %) 0 (0 %) 3 (2 %) 3 (2 %) 2 (2 %) 1 (2 %)
Second-line
therapy
101
(16 %)
101
(100 %)
57
(21 %)
57
(100 %)
44
(12 %)
44
(100 %)
37
(16 %)
37
(100 %)
25
(18 %)
25
(100 %)
12
(12 %)
12
(100 %)
Everolimus 40 (40 %) 26 (46 %) 14 (32 %) 21 (57 %) 12 (50 %) 9 (75 %)
Sorafenib 28 (28 %) 15 (26 %) 13 (30 %) 5 (14 %) 4 (16 %) 1 (8 %)
Sunitinib 14 (14 %) 8 (14 %) 6 (14 %) 1 (3 %) 1 (4 %) 0 (0 %)
Temsirolimus 11 (11 %) 4 (7 %) 7 (16 %) 3 (8 %) 2 (8 %) 1 (8 %)
Pazopanib 4 (4 %) 2 (4 %) 2 (5 %) 5 (14 %) 4 (16 %) 1 (8 %)
Bevacizumab +
IFN-a
1 (1 %) 1 (2 %) 0 (0 %) 2 (5 %) 2 (8 %) 0 (0 %)
Other 3 (3 %) 1 (2 %) 2 (5 %) 0 (0 %) 0 (0 %) 0 (0 %)
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Use of targeted therapies amongst patients with a poor
prognosis (2008–2010 Cohort)
Fifty-eight percent (376/645) of the patients in the 2008–
2010 Cohort, had a poor prognosis. 204/376 patients
(54 %) did not receive any targeted therapy. Of these pa-
tients, 9 patients received a metastasectomy (combined
with a nephrectomy). 29 of the remaining 195 patients
(15 %) who were given neither targeted therapy nor a
metastasectomy (combined with a nephrectomy) fulfilled
the SUTENT trial eligibility criteria. 172/376 (46 %) pa-
tients received a first-line treatment, which was mainly su-
nitinib (137/376; 80 %). Of the 137 patients treated with
sunitinib, 70 fulfilled the SUTENT trial eligibility criteria.
Amongst patients fulfilling SUTENT trial eligibility
criteria, older patients (OR, 0.90; p = 0.006) and patients
with more than one comorbidity (OR, 0.26; p = 0.090)
were less likely to receive sunitinib, whereas patients
with more than one metastatic site (OR, 5.38; p = 0.034)
Fig. 1 Use of first-line drugs over time per half a year (2008–2010 Cohort)
Table 3 Patient subgroups that are more of less likely to receive targeted therapy while fulfilling SUTENT trial eligibility criteria
2008–2010 Cohort: mRCC at the initial diagnosis 2011–2013 Cohort: mRCC
Intermediate prognosis
(n = 142)
Poor prognosis (n = 99) Favourable/intermediate
prognosis (n = 70)
Poor prognosis (n = 39)
No targeted
therapy (n = 40)
Sunitinib
(n = 102)
No targeted
therapy (n = 29)
Sunitinib
(n = 70)
No targeted
therapy n = 25
Sunitinib n = 45 No targeted
therapy n = 13
Sunitinib
n = 26
Sex – n (%)
Female NS NS NS NS 2 (8 %) 15 (33 %) NS NS
Male NS NS NS NS 23 (92 %) 30 (67 %) NS NS
Median age – yr (range) 71 (43–84) 62 (23–89) 71 (44–79) 61 (39–79) 72 (57–82) 63 (42–79)
Site of metastasis – n (%)
one 25 (62 %) 38 (37 %) 15 (53 %) 20 (29 %) NS NS NS NS
more than one 15 (38 %) 64 (63 %) 14 (47 %) 50 (71 %) NS NS NS NS
Neutrophil count – n (%)
normal 27 (68 %) 87 (85 %) NS NS NS NS NS NS
> ULN 13 (33 %) 15 (15 %) NS NS NS NS NS NS
Comorbidities
Zero or one NS NS 15 (52 %) 52 (74 %) NS NS NS NS
More than one NS NS 14 (48 %) 18 (26 %) NS NS NS NS
NOTE: This table shows patient subgroups that are more or less likely to receive targeted therapy (i.e. first-line sunitinib) among patients fulfilling SUTENT trial
eligibility criteria (according to the multi-level mixed-effects models). The multi-level models initially included all patient and disease characteristics as mentioned
in Table 1 (besides hospital of diagnosis). Not significant (NS) means that this variable was not significantly associated to prescription of sunitinib at α = 0.10 in a
particular risk group/cohort
Abbreviations: NS not significant
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were more likely to receive sunitinib (see frequencies in
Table 3). Furthermore, a significant association was
found between hospital of diagnosis and prescription of
sunitinib (p = 0.0059).
Median OS of eligible patients not receiving any tar-
geted therapy was 6.2 months (95 % C.I. 1.7–9.9). Table 4
shows the median OS in subgroups of patients with a
poor prognosis treated with first-line sunitinib. Median
OS of eligible patients treated with sunitinib was
6.8 months (95 % C.I. 5.3–10.7). The mean time from
diagnosis to start of first-line sunitinib was 2.9 months
(SD 5.5).
Median OS was significantly reduced in poor-prognosis
patients treated with sunitinib but not fulfilling the
Table 4 Overall survival in subgroups of patients treated with first-line sunitinib (Cohort 2008–2010 and Cohort 2011–2013)
2008–2010 Cohort: mRCC at the initial diagnosis 2011–2013 Cohort: mRCC
n Median OS in months
(95 % C.I.)
p-value n Median OS in months
(95 % C.I.)
p-value
All patients 282 9.1 (7.2–11.1) – 109 10.1 (7.2–13.8) –
Fulfilling SUTENT trial eligibility criteria No 110 6.5 (4.9–8.9) 38 6.9 (3.4–10.9)
Yes 172 11.9 (8.8–14.6) 0.0014 71 12.1 (8.9-NR) 0.0074
Brain metastases No 261 9.3 (7.6–11.9) 101 10.9 (7.8–18.0)
Yes 21 4.3 (2.1–11.5) 0.0820 8 2.5 (0.8–7.5) 0.0125
WHO performance status 0–1 248 10.3 (8.4–13.0) 100 11.3 (7.8–18.0)
2–4 34 3.3 (1.8–6.2) <0.0001 9 1.4 (0.6–7.5) <0.0001
Histology Clear cell 204 10.0 (7.6–13.3) 81 10.6 (7.2–20.3)
Non-clear cell 78 6.9 (5.4–11.0) 0.0809 28 10.0 (3.5–13.8) 0.3325
Age <65 years 162 8.9 (6.5–10.8) 64 11.3 (7.2–20.3)
> = 65 years 120 10.0 (6.5–13.8) 0.8373 45 10.0 (5.3–16.6) 0.4294
Patients with an intermediate prognosis
(or favourable prognosis)a
145 14.6 (11.5–16.0) – 65 16.6 (10.1-NR) –
Fulfilling SUTENT trial eligibility criteria No 43 11.9 (6.5–18.3) 20 10.9 (2.7-NR)
Yes 102 14.8 (10.8–16.1) 0.2897 45 18.0 (10.1-NR) 0.1212
Brain metastases No 136 14.6 (10.7–16.0) 61 16.6 (10.9-NR)
Yes 9 11.9 (4.3–29.3) 0.8072 4 6.9 (2.5-NR) 0.2282
WHO performance status 0–1 143 14.4 (10.8–16.0) 64 16.6 (10.1-NR)
2–4 2 – 0.2304 1 – 0.2471
Histology Clear cell 111 14.8 (11.8–16.2) 49 18.0 (10.0-NR)
Non-clear cell 34 11.5 (6.3–17.7) 0.1954 16 13.8 (2.7-NR) 0.3135
Age <65 years 87 10.8 (7.2–15.7) 36 12.1 (7.2-NR)
> = 65 years 58 16.1 (12.4–18.8) 0.2606 29 16.6 (8.5-NR) 0.7157
Patients with a poor prognosis 137 6.1 (4.9–7.7) – 44 6.5 (3.4–10.0) –
Fulfilling SUTENT trial eligibility criteria No 67 4.7 (3.3–6.9) 18 3.5 (1.3–7.8)
Yes 70 6.8 (5.3–10.7) 0.0145 26 6.6 (3.8-NR) 0.0720
Brain metastases No 125 6.5 (5.3–8.4) 40 6.5 (3.8–10.1)
Yes 12 2.1 (0.7–4.2) 0.0062 4 1.2 (0.8-NR) 0.0134
WHO performance status 0–1 105 6.9 (5.3–9.8) 36 6.6 (3.8–10.1)
2–4 32 3.1 (1.4–5.5) <0.0001 8 1.2 (0.6–7.5) 0.0087
Histology Clear cell 93 6.1 (4.6–7.8) 32 6.5 (2.7–10.1)
Non-clear cell 44 5.7 (3.7–10.3) 0.6585 12 4.1 (2.6-NR) 0.9982
Age <65 years 75 6.9 (4.9–9.8) 28 7.8 (3.8–13.7)
> = 65 years 62 5.4 (3.8–6.8) 0.4044 16 3.2 (1.1–6.6) 0.0256
Abbreviations: C.I, confidence interval, NR not reached
aSince all patients in the 2008–2010 Cohort presented with metastatic disease, none of the patients had a favourable prognosis (i.e. time from initial RCC
diagnosis was less than one year)
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SUTENT trial eligibility criteria (4.7 months, 95 % C.I.
3.3–6.9). Additionally, OS was significantly reduced in pa-
tients with brain metastases and patients with a WHO
performance status of 2–4.
Patient and disease characteristics of the 2011–2013
Cohort
The second cohort study included 791 patients with
(m)RCC diagnosed between 2011 and 2013. Of these pa-
tients, 233 had metastatic disease; 75 in 2011, 102 in 2012
and 55 in 2013 (one unknown). Median follow-up of the
patients with mRCC was 1.2 years (95 % C.I. 1.1–1.4).
Table 1 shows the patient and disease characteristics
of the patients with mRCC in this cohort. Median age
was 66 years, and 73 % (170/233) of the patients was
men. Metastatic disease was present in 77 % (179/233)
of patients at the time of diagnosis, whereas 23 % was
initially diagnosed with localised disease. In this cohort,
4 % of the patients with mRCC had a favourable progno-
sis, whereas 54 % and 42 % had an intermediate or poor
prognosis, respectively.
Uptake of targeted therapies and their use in daily
clinical practice (2011–2013 Cohort)
Table 2 shows the first-line therapies used in the 2011–
2013 Cohort. During the follow-up period, 139/233
(60 %) patients received a first-line therapy; the majority
(110, 79 %) was treated with sunitinib. The distribution
of patients across first-line therapies over time (half-year
periods) is presented in Fig. 2. There were no significant
differences between the half-year periods in the propor-
tion of patients receiving targeted therapies. However,
amongst treated patients, there was a decreasing trend
in sunitinib use over time (p = 0.0061) and an increasing
trend in pazopanib use (p = 0.0005).
Thirty-seven patients also received a second-line ther-
apy within the follow-up period. The majority was
treated with everolimus (57 %), but a decreasing trend in
everolimus use over time was observed (p = 0.0020).
Use of targeted therapies amongst patients with a
favourable or intermediate prognosis (2011–2013 Cohort)
136/233 patients (58 %) had a favourable or intermediate
prognosis. 52/136 patients (38 %) did not receive any
targeted therapy within the follow-up period. However,
12 of these 52 patients received a metastasectomy (com-
bined with a nephrectomy). 25 of the remaining 40 pa-
tients (63 %) who were given neither targeted therapy
nor a metastasectomy (combined with a nephrectomy)
fulfilled the SUTENT trial eligibility criteria. In addition,
45 of the 66 patients treated with sunitinib fulfilled the
SUTENT trial eligibility criteria.
Amongst patients fulfilling SUTENT trial eligibility
criteria, males (OR, 0.12; p = 0.020) and older patients
(OR, 0.92; p = 0.011) were less likely to receive sunitinib
after adjustment for additional patient and disease char-
acteristics (see frequencies in Table 3).
Median OS of eligible patients not receiving any tar-
geted therapy was 20.9 months (95 % C.I. 7.4-not
reached [NR]). Table 4 presents the median OS in sub-
groups of patients with a favourable or intermediate
prognosis treated with first-line sunitinib. Median OS of
eligible patients treated with sunitinib was 18.0 months
(95 % C.I. 10.1-NR). The mean time from diagnosis to
start of first-line sunitinib was 2.1 months (SD 3.3).
Median OS was 10.9 months (95 % C.I. 2.7-NR) for pa-
tients treated with sunitinib but not fulfilling SUTENT
trial eligibility criteria. No significant differences were ob-
served within subgroups.
Fig. 2 Use of first-line drugs over time per half a year (2011–2013 Cohort)
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Use of targeted therapies amongst patients with a poor
prognosis (2011–2013 Cohort)
97/233 patients (42 %) had a poor prognosis. Forty-two
patients (43 %) did not receive any targeted therapy;
thirteen of these 42 patients (31 %) fulfilled the
SUTENT trial eligibility criteria. Of the 44 patients
treated with sunitinib, 26 fulfilled the SUTENT trial eli-
gibility criteria.
Of patients fulfilling SUTENT trial eligibility criteria,
older patients (OR, 0.84; p = 0.012) were less likely to re-
ceive sunitinib (see frequencies in Table 3). The un-
adjusted model showed a significant association between
hospital of diagnosis and the prescription of sunitinib,
but this association disappeared after adjustment for
demographics, clinical and laboratory factors.
Median OS of eligible patients not receiving any targeted
therapy was 3.4 months (95 % C.I. 0.8- NR). Table 4 shows
the median OS in subgroups of patients with a poor prog-
nosis treated with first-line sunitinib. Median OS of eligible
patients treated with sunitinib was 6.6 months (95 % C.I.
3.8-NR). The mean time from diagnosis to start of first-line
sunitinib was 1.9 months (SD 1.8).
Median OS was significantly reduced in patients not
fulfilling the SUTENT trial eligibility criteria (3.5 months,
95 % C.I. 1.3–7.8). Additionally, as in the 2008–2010
Cohort, median OS was significantly reduced in patients
with brain metastases and patients with a WHO per-
formance status of 2–4. OS was also significantly re-
duced in older patients.
Discussion
Since 2006, several new targeted therapies for mRCC
have entered the market and randomised controlled trial
(RCTs) have shown that these therapies improve survival
[4, 5, 9, 16–27]. This study examined the uptake and use
of targeted therapies in The Netherlands. Not unex-
pected, targeted therapies, sunitinib in particular, have
largely replaced IFN-a as first-line standard of care. Few
patients were treated with bevacizumab (combined with
IFN-a) or temsirolimus in the 2008–2013 period, even
though these therapies were added to the ESMO guide-
lines in 2009 [6], and to Dutch guidelines in 2010 [6].
Pazopanib has only been recommended since 2010 [8],
which partly explains why an increase in its use was only
seen from 2012. Furthermore, there was a shift in the
use of second-line therapies, where sorafenib was re-
placed by everolimus as the most frequent choice from
2010 onwards.
The median OS of patients with an intermediate prog-
nosis treated with sunitinib in Dutch daily practice and
fulfilling the SUTENT trial eligibility criteria was shorter
than the median OS of patients in the SUTENT trial with
an intermediate prognosis, i.e. 14.8 months (95 % C.I.
10.8–16.1) in the 2008–2010 Cohort compared to
20.7 months (95 % C.I. 18.2–25.6) in the SUTENT trial
[5]. However, the difference was much smaller for the
2011–2013 Cohort (median OS, 18.0 months (95 % C.I.
10.1-NR)) compared to the SUTENT trial patients. Me-
dian OS of patients with a poor prognosis fulfilling the
SUTENT trial eligibility criteria was similar to the median
OS found in the SUTENT trial, i.e. 6.8 months (95 % C.I.
5.3–10.7) in the 2008–2010 Cohort and 6.6 months (95 %
C.I. 3.8-NR) in the 2011–2013 Cohort compared to
5.3 months (95 % C.I. 4.2–10.0) in the SUTENT trial [5].
The median OS of patients with an intermediate prog-
nosis treated with sunitinib in Dutch daily practice (re-
gardless of their SUTENT trial eligibility status) was
shorter than the OS in the expanded-access trial [7].
Median OS of patients with a poor prognosis was in line
with the results of the expanded-access trial. The median
OS of patients with an intermediate prognosis treated
with sunitinib in Dutch daily practice was also shorter
than the OS in a retrospective, non-interventional study
in Australia [28]. These findings may indicate that the
patients in the PERCEPTION registry with an inter-
mediate risk had a worse prognosis than the patients
with an intermediate risk in other studies.
While previous studies suggest that patients fulfilling
SUTENT trial eligibility criteria have a survival benefit
from first-line sunitinib [5], many eligible patients did
not receive sunitinib (or any other targeted therapy) in
daily practice. This was also seen in England where one
in three patients with mRCC eligible for either sunitinib
or pazopanib did not receive the drug [29]. Patients aged
65+ years were less likely to receive targeted therapy
than younger patients after adjustment for other factors.
This age factor was found in patients with an intermedi-
ate prognosis (2011–2013 Cohort) and in patients with a
poor prognosis (2008–2010 Cohort and 2011–2013 Co-
hort). There are several explanations for this association,
including medical contraindications, other grounds for
physician reluctance, and patient refusal. Additionally,
patients with one metastatic site were less likely to re-
ceive sunitinib (according to the 2008–2010 Cohort re-
sults), which might be explained by patients with low
volume but unresectable metastases whose targeted
therapy is delayed. Nevertheless, most of these patients
died within the follow-up period without receiving tar-
geted therapy at any point in time. The reasons for ap-
parent underutilisation of targeted therapies should be
examined more carefully. While hospital-level factors
may also affect utilisation and lead to between-hospital
variation, we found no significant differences in the pre-
scription of targeted therapy between hospitals, except
for the patients with a poor prognosis in the 2008–2010
Cohort. However, the sample size per hospital was small
and the statistical power to show a difference was there-
fore limited.
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Although this study mainly focussed on patients fulfill-
ing SUTENT trial eligibility criteria, we found that many
patients in daily clinical practice are different from pa-
tients included in RCTs. In the total study population,
only 42 % and 58 % fulfilled the SUTENT trial eligibility
criteria in the 2008–2010 Cohort and 2011–2013
Cohort, respectively. This was partly caused by the inclu-
sion criteria of the PERCEPTION registry, which con-
sisted of a diagnosis of mRCC (i.e. metastases at initial
presentation in the 2008–2010 Cohort) of any histological
subtype. Since many patients are excluded from clinical
trials, such as patients with a non clear-cell subtype, pa-
tients with a WHO performance status of 2 to 4 and pa-
tients with brain metastases, one could argue that the
results of these trials only apply to a subgroup of patients.
A limitation of this study is the amount of missing
data in baseline characteristics, which is inherent to an
observational study. To overcome this problem, multiple
imputations by chained equations were conducted,
which ensure that all patients are included in the ana-
lysis but simultaneously ensure that the uncertainties
from missing data are retained [15]. Additionally, eligi-
bility criteria, such as the presence of measurable disease
and adequate organ function were not taken into ac-
count when determining whether patients fulfilled the
SUTENT trial eligibility criteria, since data on these cri-
teria were lacking in the PERCEPTION registry. As a
consequence, some of the patients that we labelled as
eligible in this study were not in fact eligible for targeted
therapy. However, since we used WHO performance sta-
tus to classify patients, and since we expect a relation-
ship between WHO performance status and organ
function, we believe that this could only have had a lim-
ited effect on our conclusions about the uptake and use
of targeted therapies. Furthermore, the follow-up length
of the 2011–2013 Cohort was limited. As a consequence,
patients might have received targeted therapy after the
follow-up period, leading to an underestimate of actual
targeted therapy use. However, this limitation is only
relevant for patients treated later in the 2011–2013
period who did not die. Lastly, OS was calculated from
the date of diagnosis (i.e. metastatic disease) for patients
not receiving any targeted therapy and from the start of
therapy for patients treated with targeted therapy; as a
consequence a comparison between the two is impos-
sible. This approach was based on the one used in other
studies to enable comparisons between the OS of pa-
tients treated with sunitinib in our study with the OS of
patients treated with sunitinib in other studies [5, 7, 28].
Conclusions
In conclusion, targeted therapies, sunitinib in particular,
have largely replaced IFN-a as the first-line standard of
care in The Netherlands. Nevertheless, many patients in
Dutch daily practice fulfilling SUTENT trial eligibility
criteria did not receive sunitinib (or any other targeted
therapy) even though it could improve their survival. For
example, older patients were less likely to receive suniti-
nib, perhaps because physicians are reluctant to pre-
scribe it. The reasons for apparent underutilisation of
targeted therapies should be examined more carefully.
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